EGF is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Palmitoyl Tripeptide-1 FDA approved?

Palmitoyl Tripeptide-1 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is EGF administered in research settings?

In research settings, EGF is typically administered via the topical, subcutaneous, or microneedling routes. PeptideBase does not provide dosing or administration instructions.

How is Palmitoyl Tripeptide-1 administered in research settings?

In research settings, Palmitoyl Tripeptide-1 is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›EGF vs Palmitoyl Tripeptide-1

Peptide Comparison

EGF vs Palmitoyl Tripeptide-1

Q: What is the difference between EGF and Palmitoyl Tripeptide-1?

EGF: Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Palmitoyl Tripeptide-1: Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Both are Skin & Cosmetic peptides.

EGF

Epidermal Growth Factor

Skin & JointNot EvaluatedResearch Only

No providers listed yet

Full EGF profile →

Palmitoyl Tripeptide-1

Pal-GHK

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

4 providers listed

Full Palmitoyl Tripeptide-1 profile →

Bottom line

EGF carries stronger published evidence (Cohort study, 3 key studies) than Palmitoyl Tripeptide-1 (Review, 2); both are research compounds.

Quick Verdict

EGF

Evidence

Observational

Palmitoyl Tripeptide-1

Evidence

Preclinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	EGF
More provider options (0 vs 4)	Palmitoyl Tripeptide-1

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

EGF

Palmitoyl Tripeptide-1

Mechanism Family

Skin & Cosmetic

Half-life

—

N/A (topical)

FDA Status

not evaluated

Admin Routes

topical, subcutaneous, microneedling

topical

Availability

Research Only

Providers

None listed

4 listed

Avail. Notes

—

Cosmetic peptide (Pal-GHK, palmitoyl tripeptide-1). Palmitate conjugate of GHK tripeptide. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-aging ingredient only.

Research Evidence

EGF

ObservationalCohort study · 3 key studies · most recent 2026

Palmitoyl Tripeptide-1

PreclinicalReview · 2 key studies · dated evidence base — most recent 2015

Research Citations

EGF

Review2026 · Cell Tissue Bank

Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and bioc…

Cohort2026 · Gels

Development of Antiseptic and Epidermal Growth Factor Co-Loaded Thermoresponsive Composite Hydrogel for Wound…

Cohort2009 · International Wound Journal

The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary resu…

Palmitoyl Tripeptide-1

Review2015 · BioMed Research International

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

In vitro2012 · Journal of Peptide Science

Stem cell recovering effect of copper-free GHK in skin

About EGF

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Research Areas

skin regenerationwound healingcollagen stimulationpost-procedure recovery

About Palmitoyl Tripeptide-1

Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Research Areas

collagen synthesisskin firmnessanti-agingwound healing

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

EGF

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Palmitoyl Tripeptide-1

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

EGF

Browse directory →

Providers offering

Palmitoyl Tripeptide-1

4 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.